Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients - PubMed (original) (raw)
Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients
L Ryysy et al. Diabetes. 2000 May.
Abstract
To determine causes of interindividual variation in insulin requirements, we recruited 20 type 2 diabetic patients with stable glucose control and insulin doses for >1 year on combination therapy with bedtime NPH insulin and metformin. Insulin absorption (increase in free and total insulin over 8 h after a subcutaneous dose of regular insulin) and actions of intravenous (6-h 0.3 mU x kg(-1) x min(-1) euglycemic insulin clamp combined with [3-3H]glucose) and subcutaneous (glucose infusion rate required to maintain isoglycemia and suppression of free fatty acids [FFAs]) insulin, liver fat content (proton spectroscopy), visceral fat (magnetic resonance imaging), weight, and body composition were determined. We found the following variation in parameters: insulin dose range 10-176 U (mean 42 U, fold variation 17.6x) or 0.13-1.39 U/kg (0.44 U/kg, 10.7x), absorbed insulin 10.6x, action of subcutaneous insulin to suppress FFAs 7.5 x and to stimulate glucose metabolism (M value) 11.5x, body weight 67-127 kg (91 kg, 1.9x), liver fat 2-28% (12%, 14x), and visceral fat 179-2,053 ml (1,114 ml, 11.5x). The amount of insulin absorbed, measured as either free or total insulin, was significantly correlated with its ability to suppress FFAs and stimulate glucose metabolism but not with the insulin dose per se. The actions of absorbed insulin were, on the other hand, significantly correlated with the daily insulin dose (r = 0.70 for action on FFAs, P < 0.001, and r = -0.61 for M value, P < 0.005). Actions of subcutaneous and intravenous insulin to suppress FFAs were significantly correlated (r = 0.82, P < 0.001, R2 = 67%). Of the measures of adiposity, the percent hepatic fat was the parameter best correlated with the daily insulin dose (r = 0.76, P < 0.001). The percent hepatic fat was also significantly correlated with the ability of intravenous insulin to suppress endogenous glucose production (r = 0.72, P < 0.005). We conclude that the major reason for interindividual variation in insulin requirements in type 2 diabetes is the variation in insulin action. Variation in hepatic fat content may influence insulin requirements via an effect on the sensitivity of endogenous glucose production to insulin.
Similar articles
- Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.
Juurinen L, Kotronen A, Granér M, Yki-Järvinen H. Juurinen L, et al. J Clin Endocrinol Metab. 2008 Jan;93(1):118-24. doi: 10.1210/jc.2007-1825. Epub 2007 Oct 23. J Clin Endocrinol Metab. 2008. PMID: 17956948 - Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA. Miyazaki Y, et al. J Clin Endocrinol Metab. 2002 Jun;87(6):2784-91. doi: 10.1210/jcem.87.6.8567. J Clin Endocrinol Metab. 2002. PMID: 12050251 - Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes.
Kotronen A, Juurinen L, Tiikkainen M, Vehkavaara S, Yki-Järvinen H. Kotronen A, et al. Gastroenterology. 2008 Jul;135(1):122-30. doi: 10.1053/j.gastro.2008.03.021. Epub 2008 Mar 21. Gastroenterology. 2008. PMID: 18474251 - The fatty liver and insulin resistance.
Yki-Järvinen H, Westerbacka J. Yki-Järvinen H, et al. Curr Mol Med. 2005 May;5(3):287-95. doi: 10.2174/1566524053766031. Curr Mol Med. 2005. PMID: 15892648 Review. - Fat-induced liver insulin resistance.
Shah P, Basu A, Rizza R. Shah P, et al. Curr Diab Rep. 2003 Jun;3(3):214-8. doi: 10.1007/s11892-003-0066-1. Curr Diab Rep. 2003. PMID: 12762968 Review.
Cited by
- Unlocking the Potential of Type 2 Diabetes Mellitus Remission.
Sharma P, Chakole S. Sharma P, et al. Cureus. 2023 Nov 12;15(11):e48704. doi: 10.7759/cureus.48704. eCollection 2023 Nov. Cureus. 2023. PMID: 38094528 Free PMC article. Review. - Relationship between Uric Acid to High Density Lipoprotein Cholesterol Ratio and Nonalcoholic Fatty Liver Disease in Nonoverweight/Obese Patients with Type 2 Diabetes.
Cui Y, Qu Z, Hu W, Shi H. Cui Y, et al. Int J Endocrinol. 2023 Aug 1;2023:2513175. doi: 10.1155/2023/2513175. eCollection 2023. Int J Endocrinol. 2023. PMID: 37560201 Free PMC article. - Insights into the development of insulin resistance: Unraveling the interaction of physical inactivity, lipid metabolism and mitochondrial biology.
Handy RM, Holloway GP. Handy RM, et al. Front Physiol. 2023 Apr 20;14:1151389. doi: 10.3389/fphys.2023.1151389. eCollection 2023. Front Physiol. 2023. PMID: 37153211 Free PMC article. Review. - The Health-Promoting Effects and the Mechanism of Intermittent Fasting.
Liu S, Zeng M, Wan W, Huang M, Li X, Xie Z, Wang S, Cai Y. Liu S, et al. J Diabetes Res. 2023 Mar 3;2023:4038546. doi: 10.1155/2023/4038546. eCollection 2023. J Diabetes Res. 2023. PMID: 36911497 Free PMC article. Review. - Prevalence and Specific Manifestations of Non-alcoholic Fatty Liver Disease (NAFLD) and Diabetes Mellitus Type 2 Association in a Moroccan Population: A Cross-sectional Study.
Assarrar I, Messaoudi N, Ongoth FEM, Abdellaoui W, Malki A, Rouf S, Abda N, Ismaili Z, Latrech H. Assarrar I, et al. Rev Diabet Stud. 2022 Sep 28;18(3):140-145. doi: 10.1900/RDS.2022.18.140. Rev Diabet Stud. 2022. PMID: 36309775 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous